The assumption was that whatever the risks of legalizing therapeutic MDMA, the crisis of PTSD gripping the country (and doing ...

The US Food and Drug Administration's (FDA) decision not to approve midomafetamine-assisted therapy (MDMA-AT) for ...

In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) ...

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024.

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay ...

In June 2024, an FDA advisory committee voted overwhelmingly against the idea that the relevant clinical trials had proved the efficacy of MDMA for the treatment of PTSD. Just as decisively ...

As Psychiatric Times reported, this decision puts on hold what could have been a landmark approval for the treatment of PTSD with MDMA, also known as midomafetamine. Despite the setback, Lykos ...

WASHINGTON — Federal health regulators on Friday declined to approve the psychedelic drug MDMA as a therapy for PTSD, a major setback for groups seeking a breakthrough decision in favor of using ...

In view of the ... in PTSD symptoms among military veterans, particularly in reducing avoidance behaviors and hyper-arousal – key components of PTSD. Comparative research between MDMA and ...

It is considered to be more pleasure-inducing than other amphetamines, and for this reason, it has been a popular party drug. Some researchers call MDMA an “empathogen” or a “feeling enhancer.” PTSD ...